NorthX Biologics AB
Swedish contract development and manufacturing organization (CDMO) focused on development and GMP manufacturing for advanced biologics. Offers end-to-end CMC support across modalities including recombinant proteins, viral vaccines and vectors, plasmid DNA, cell therapies and extracellular vesicles. Operates multiple sites in Sweden and provides process development, scale-up, analytical testing, aseptic fill & finish and technology transfer services.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Development and optimization of manufacturing processes from early development to clinical and commercial readiness.
Comprehensive analytical testing tailored to biologic modalities to support development and release testing.
Gene-to-protein services including cloning, expression, cell banking and downstream purification across microbial and mammalian systems.
End-to-end manufacturing services for viral vaccines, oncolytic viruses and viral vectors across pre-clinical to commercial stages.
Production of plasmid DNA suitable for use in DNA vaccines, viral vector production and mRNA workflows from pre-clinical to commercial scales.
Clinical-focused cell therapy manufacturing and delivery services with flexible solutions for different cell types.
Development and optimization of manufacturing processes from early development to clinical and commercial readiness.
Comprehensive analytical testing tailored to biologic modalities to support development and release testing.
Gene-to-protein services including cloning, expression, cell banking and downstream purification across microbial and mammalian systems.
End-to-end manufacturing services for viral vaccines, oncolytic viruses and viral vectors across pre-clinical to commercial stages.
Production of plasmid DNA suitable for use in DNA vaccines, viral vector production and mRNA workflows from pre-clinical to commercial scales.
Clinical-focused cell therapy manufacturing and delivery services with flexible solutions for different cell types.
Expertise Areas
- Bioprocessing and scale-up
- CMC development and manufacturing
- Analytical testing and QC for biologics
- Recombinant protein production
Key Technologies
- GMP manufacturing
- Process development and scale-up
- Gene cloning and cell bank generation
- Protein expression and purification
News & Updates
Announcement of a growth investment from a healthcare private equity firm to support company expansion.
Partnership to accelerate development of a gene therapy toward clinical trials.
Official accreditation by a national research tax credit program to support R&D collaboration.
Appointment of a Chief Operating Officer to the leadership team.
Collaboration to advance manufacturing strategies for a personalized cancer cell therapy.
Announcement of a growth investment from a healthcare private equity firm to support company expansion.
Partnership to accelerate development of a gene therapy toward clinical trials.
Official accreditation by a national research tax credit program to support R&D collaboration.
Appointment of a Chief Operating Officer to the leadership team.
Collaboration to advance manufacturing strategies for a personalized cancer cell therapy.